Copyright © 1991 by the European Society of Cardiology.
© 1991 The European Society of Cardiology
Decreased peripheral bone mineral content in patients under anticoagulant therapy with phenprocoumon
,
*Medical Department, Krankenhaus der Barmherzigen Br
der A-1020 Vienna
Department of Medicine II, University of Vienna A-1090 Vienna
Ludwig Boltzmann Institute of Geriatrics and Gerontology A-1090 Vienna, Austria
Received 24 November 1989; revised 17 April 1990; .
Correspondence: Dr H. Resch, Medical Department, K.H der Barmherrigen Brder, GroBe Mohrengasse 9, A-1020 Vienna, Austria.
Abstract
In experimental and clinical studies, conflicting results regarding the effect of oral anticoagulant therapy on bone metabolism have been reported. To measure a possible influence of long-term anticoagulant therapy with phenprocoumon on peripheral bone mass, measurements of peripheral bone mineral content (BMC) and serum osteocalcin levels were performed with single photon absorptiometry in a total of 78 patients on anticoagulant treatment. We studied 43 women (mean age 66 years ± 2 SEM) and 35 men (mean age 65 years ± 2 SEM) with a median duration of phenprocoumon therapy of I year (1–9 years). In all patients, the medical history gave no symptoms of metabolic bone disease, or diseases or medications causing osteoporosis.
Both in the male and female groups, mean peripheral BMC was significantly decreased (male: P<0.01, female: P<0.003) when compared with corresponding controls. Serum OC-levels measured in 16 patients were also significantly lower than those of the controls (P<0.02).
Our data of decreased BMC and low serum OC-levels indicate reduced bone mass in patients on long-term anticoagulant therapy with phenprocoumon. This may imply an influence of anticoagulants on bone metabolism resulting in decreased bone format ion.
Key Words: Bone mineral content • osteocalcin • phenprocoumon • anticoagulant therapy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. J. Schurgers, M. J. Shearer, K. Hamulyak, E. Stocklin, and C. Vermeer Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects Blood, November 1, 2004; 104(9): 2682 - 2689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. C Binkley, D. C Krueger, J. A Engelke, A. L Foley, and J. W Suttie Vitamin K supplementation reduces serum concentrations of under-{gamma}-carboxylated osteocalcin in healthy young and elderly adults Am. J. Clinical Nutrition, December 1, 2000; 72(6): 1523 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Caraballo, J. A. Heit, E. J. Atkinson, M. D. Silverstein, W. M. O'Fallon, M. R. Castro, and L. J. Melton III Long-term Use of Oral Anticoagulants and the Risk of Fracture Arch Intern Med, August 9, 1999; 159(15): 1750 - 1756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Feskanich, P. Weber, W. C Willett, H. Rockett, S. L Booth, and G. A Colditz Vitamin K intake and hip fractures in women: a prospective study Am. J. Clinical Nutrition, January 1, 1999; 69(1): 74 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Sels, J. Dequeker, J. Verwilghen, and J-M. Mbuyi-Muamba SLE and osteoporosis: dependence and/or independence on glucocorticoids Lupus, April 1, 1996; 5(2): 89 - 92. [PDF]
|
|